Stevens Capital Management LP bought a new position in Laboratory Corporation of America Holdings (NYSE:LH) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 18,052 shares of the medical research company’s stock, valued at approximately $2,725,000.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in Laboratory Corporation of America Holdings by 2.3% in the second quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock worth $1,597,181,000 after purchasing an additional 231,600 shares in the last quarter. Boston Partners raised its holdings in Laboratory Corporation of America Holdings by 4.8% in the second quarter. Boston Partners now owns 4,590,372 shares of the medical research company’s stock worth $707,560,000 after purchasing an additional 210,138 shares in the last quarter. Nordea Investment Management AB raised its holdings in Laboratory Corporation of America Holdings by 2.0% in the second quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after purchasing an additional 54,100 shares in the last quarter. FMR LLC raised its holdings in Laboratory Corporation of America Holdings by 9.4% in the second quarter. FMR LLC now owns 1,780,950 shares of the medical research company’s stock worth $274,516,000 after purchasing an additional 153,546 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Laboratory Corporation of America Holdings by 70.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,543,126 shares of the medical research company’s stock worth $237,857,000 after purchasing an additional 637,848 shares in the last quarter. Institutional investors and hedge funds own 93.84% of the company’s stock.

In other Laboratory Corporation of America Holdings news, CEO David P. King sold 132,713 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $157.06, for a total value of $20,843,903.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider F Samuel Eberts III sold 31,500 shares of the company’s stock in a transaction that occurred on Friday, August 25th. The stock was sold at an average price of $155.22, for a total value of $4,889,430.00. Following the completion of the sale, the insider now owns 31,894 shares in the company, valued at approximately $4,950,586.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 209,871 shares of company stock worth $32,892,005. 0.90% of the stock is owned by insiders.

LH has been the subject of a number of recent research reports. Barclays PLC reiterated an “overweight” rating and issued a $182.00 target price (up from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday, July 17th. Craig Hallum restated a “buy” rating and set a $179.00 price objective (up previously from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. Morgan Stanley upped their price objective on shares of Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Finally, ValuEngine upgraded shares of Laboratory Corporation of America Holdings from a “hold” rating to a “buy” rating in a report on Wednesday, September 6th. Seven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Laboratory Corporation of America Holdings presently has a consensus rating of “Buy” and a consensus target price of $169.00.

Shares of Laboratory Corporation of America Holdings (LH) opened at $150.46 on Friday. The company has a market capitalization of $15,482.76, a P/E ratio of 16.35, a P/E/G ratio of 1.61 and a beta of 0.87. Laboratory Corporation of America Holdings has a 52-week low of $123.36 and a 52-week high of $164.22. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.89 and a quick ratio of 1.75.

Laboratory Corporation of America Holdings (NYSE:LH) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.08. The firm had revenue of $2.60 billion for the quarter, compared to analyst estimates of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. Laboratory Corporation of America Holdings’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 earnings per share. equities analysts expect that Laboratory Corporation of America Holdings will post 9.52 EPS for the current year.

TRADEMARK VIOLATION WARNING: This article was published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/11/stevens-capital-management-lp-invests-2-73-million-in-laboratory-corporation-of-america-holdings-lh-stock.html.

Laboratory Corporation of America Holdings Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corporation of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.